// App-Quantinova.ai

BSH19‐PO‐080 : Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Haematopoietic Cell Transplantation: Extended Follow‐Up of the Phase 2 Multi‐Cohort CheckMate 205 Study

Researchers

Presenter

  • G. Collins

Principal Investigators

  • P. Armand

  • A. Engert

  • A. Younes

  • H.J. Lee

  • A. Santoro

  • P.L. Zinzani

  • J. Timmerman

  • R. Ramchandren

  • J. Cohen

  • J.P. De Boer

  • K. Savage

  • J. Kuruvilla

  • M. Trnen

  • M. Shipp

  • M. Sacchi

  • A. Sumbul

  • S. Ansell

Medical Centers

  • Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom

  • Dana-Farber Cancer Institute, Boston, MA, United States

  • University of Cologne, Cologne, DE, Germany

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Humanitas Cancer Center, Humanitas University, Milan

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • University of California, Los Angeles, Los Angeles, CA

  • Barbara Ann Karmanos Cancer Institute, Detroit, MI

  • Winship Cancer Institute of Emory University,Atlanta, GA,Vereinigte Staaten

  • The Netherlands Cancer Institute, Antoni Van Leeuwenhoek Hospital, Amsterdam, Netherlands

  • BC Cancer, Vancouver

  • University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Mayo Clinic, Rochester, United States

Locations

  • United Kingdom

  • United States

  • Germany

  • Italy

  • Netherlands

  • Canada

  • Czech Republic

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

Biomarkers

  • Hematocrit

Drug/Treatment

  • Adcetris

  • Nivolumab

  • Techniclone TNT

Outcome

  • N/A

Study Design

  • Multinational

  • Cohort

Phase

  • II

Study Id's

  • NCT02181738

Sponsors

  • Bristol-Myer Squibb

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved